BioAscent scientists help identify potential new treatments for cancer

30 Dec 2019

Collaboration discovers potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.

BioAscent scientists, working in collaboration with teams at the German Cancer Research Center (DKFZ) and the Pivot Park Screening Centre as part of the European Lead Factory project, have helped to discover potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases. The findings represent an initial step in the development of potential new cancer treatments.

BioAscent scientists help identify potential new treatments for cancer

The DKFZ is the largest biomedical research institute in Germany with over 1,200 scientists in over 90 divisions and research groups working on cancer research. As part of their research, one of the DKFZ teams proposed a role for Kallikrein-related peptidase 6 (KLK6) in the development, invasiveness and metastasis of some cancers, including colon cancer and melanomas. Having suggested this biological pathway, they wanted to identify compounds that inhibited KLK6 activity to test their hypothesis and identify starting points for a drug discovery project.

After an initial high throughput screen performed by the Pivot Park Screening Centre had identified a cluster of initial hits that showed consistent inhibitory activity against KLK6, the hits were validated and improved by a team of biologists and chemists, who have since transitioned to BioAscent. Using their expertise in medicinal and synthetic chemistry, novel chiral compounds were efficiently prepared using multi-step synthesis procedures and tested using a range of biophysical and biochemical assays. Using an iterative and rational design-make-test approach driven by structure-guided design, the team rapidly developed highly effective chemical leads against KLK6, with single digit nanomolar potency and good to excellent selectivity. Subsequent profiling found that one of these compounds reduced the invasion of colon cancer (HCT116) cells in a dose-dependent manner.

These approaches underline the strengths of combining a first-rate scientific team and access to state-of-the-art instrumentation that BioAscent now offers, as Dr Phil Jones, Chief Scientific Officer at BioAscent, explained: “Historically the infrastructure and expertise to carry out this type of approach has only really been available in major pharma companies. BioAscent now has the facilities and breadth of expertise and experience to perform these studies and provide our clients with excellent opportunities to advance their drug discovery projects.”

Dr Aubry Miller, Cancer Drug Discovery/Wirkstoffforschung Group Leader, DKFZ, was enthusiastic about the collaboration, commenting: “More importantly, the scientists (now at BioAscent) who were involved in the hit development stage, were fully committed to the success of the project, bringing their own ideas and solutions, which made my role as project owner very comfortable. I would be very happy to work with them again.”

Following the delivery of a number of successful projects, BioAscent’s team of chemists has grown rapidly over the last year, complementing the biology team and enabling the company to offer a fully integrated drug discovery service. As well as medicinal, synthetic and computational chemistry, the company offers de novo assay development, target analysis and bespoke screening strategies, compound screening, as well as compound management, and access to a library of 125K lead-like compounds.

“Our expansion has continued over the 18 months or so since BioAscent became a full-service CRO,” said Paul Smith, BioAscent’s CEO. “This expansion has been based on constantly delivering quality science in a timely manner for our clients. Of course, as a CRO, we can’t often talk about the work in which our scientists have been involved, so it’s good when this can be published in the peer-review journals.”

Read More

Related news

Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD

Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD

21 Feb 2020

Beovu is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on 3-month dosing intervals immediately after the loading phase.

Read more 
Catalent to manufacture first-in-class mAb targeting solid tumours

Catalent to manufacture first-in-class mAb targeting solid tumours

11 Feb 2020

ZM008 could have potential benefits for the treatment of prostate cancer.

Read more 
BD completes clinical trial for its wearable injector

BD completes clinical trial for its wearable injector

11 Feb 2020

The pre-filled, pre-assembled injector is designed to prioritize safety, convenience and usability while delivering high-value drug treatments in the comfort of an in-home environment.

Read more 
New Velesco Pharma clinical manufacturing facility begins operations

New Velesco Pharma clinical manufacturing facility begins operations

5 Feb 2020

The facility will triple the company’s cGMP clinical trial manufacturing capacity.

Read more 
Inovio and Beijing Advaccine to advance vaccine against Coronavirus

Inovio and Beijing Advaccine to advance vaccine against Coronavirus

30 Jan 2020

Agreement will facilitate clinical trial translations in China.

Read more 
First human trial of monoclonal antibody to prevent malaria opens

First human trial of monoclonal antibody to prevent malaria opens

28 Jan 2020

If proven safe and effective, mAb CIS43LS might be used prophylactically by tourists, medical workers or military personnel who travel to areas where malaria is common.

Read more 
Thermo launches next-generation, compressor-free plate sealer

Thermo launches next-generation, compressor-free plate sealer

28 Jan 2020

Features new functionalities and capabilities making it versatile for a variety of both manual and automated microplate processing life science applications.

Read more 
Merck invests in biotech development facility in Switzerland

Merck invests in biotech development facility in Switzerland

27 Jan 2020

€250 million to be invested during the 2019-2022 period in new facility bridging research and manufacturing.

Read more 
Grey Wolf Therapeutics secures funding for cancer therapies development

Grey Wolf Therapeutics secures funding for cancer therapies development

21 Jan 2020

The company targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumours for attack and destruction by the immune system.

Read more 
Diabetes diagnosis - now a matter of sweat and tears?

Diabetes diagnosis - now a matter of sweat and tears?

21 Jan 2020

No need to draw blood; researchers develop smart technology to diagnose diabetes and treat diabetic retinopathy.

Read more